Eli Lilly (LLY) Hits High After Diabetes Drug Approval

Eli Lilly (LLY) is higher after Chinese regulators approve diabetes drug in China. Diane King Hall discusses this as Eli Lilly’s Phase 3 study of Crohn’s disease treatment achieves “meaningful improvements.” Eli Lilly hit a new all-time high today. Tune in to find out more about the stock market today.

Next Gen Investing

21 May 2024

SHARE

Schwab Network's Newsletters

Daily insights for every investor

ON AIR
11:00 pm
The Wrap
replay
12:00 am
The Wrap
REPLAY
12:30 am
Market On Close
REPLAY
2:00 am
Trading 360
REPLAY
3:00 am
Fast Market
REPLAY
4:00 am
Next Gen Investing
REPLAY
5:00 am
Market Overtime
REPLAY
5:30 am
The Wrap
REPLAY
7:00 am
Morning Movers
8:00 am
Opening Bell With Nicole Petallides
9:00 am
Morning Trade Live
10:00 am
Trading 360
11:00 am
Fast Market
12:00 pm
Next Gen Investing
1:00 pm
The Watch List
2:00 pm
Market On Close
3:30 pm
Market Overtime
REPLAY
4:00 pm
Fast Market
REPLAY
5:00 pm
Next Gen Investing
REPLAY
6:00 pm
The Wrap
REPLAY
7:30 pm
Market Overtime
REPLAY
8:00 pm
Market Overtime
REPLAY
8:30 pm
Market On Close
REPLAY
10:00 pm
Trading 360
REPLAY
ON AIR
11:00 pm
The Wrap
REPLAY